Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

AWIQLI 1050 UNIT / 1.5 ML

INSULIN ICODEC : 1050 UNIT / 1.5 ML · DIN 02546213 · NOVO NORDISK CANADA INC

Health Canada status: MARKETED

What is AWIQLI?

AWIQLI 1050 UNIT / 1.5 ML contains INSULIN ICODEC : 1050 UNIT / 1.5 ML. It is listed in the Health Canada Drug Product Database under DIN 02546213, held by NOVO NORDISK CANADA INC, supplied as SOLUTION for SUBCUTANEOUS administration. Health Canada currently lists it as marketed, status dated 13-Jun-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.

What is AWIQLI used for?

Once-weekly treatment of adults with diabetes mellitus to improve glycemic control.

Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.

Product details and regulatory record

DIN02546213
Brand nameAWIQLI
Generic / active ingredientINSULIN ICODEC : 1050 UNIT / 1.5 ML
ManufacturerNOVO NORDISK CANADA INC
Strength1050 UNIT / 1.5 ML
Dosage formSOLUTION
Route of administrationSUBCUTANEOUS
ScheduleSchedule D
ATC codeA10AE07 INSULIN ICODEC
BiosimilarNo
Health Canada statusMARKETED
Status date13-Jun-2024

How is it administered?

Subcutaneous once-weekly injection. Starting dose for insulin-naïve T2DM is 70 units. For switching from daily basal insulin, weekly dose is daily dose x 7. Optional 50% one-time additional dose for week 1.

Included because it drives pack selection and wastage. Consult the monograph.

How is it stored and handled?

Not explicitly detailed in the provided text snippet (refer to section 11), but standard insulin storage usually applies.

How is it supplied?

1, 1.5 or 3 mL solution in a cartridge contained in a pre-filled multidose disposable FlexTouch pen. Available in 1 pen/pack.

Contraindications

During episodes of hypoglycemia; patients who are hypersensitive to this drug or to any ingredient in the formulation.

Warnings and precautions

Hypoglycemia risk; do not mix with other insulins; do not use in insulin pumps; medication errors (do not confuse with daily insulin); rotate injection sites; never share pens.

What can be used instead?

Other Canadian products sharing ATC code A10AE07 INSULIN ICODEC. 3 of 3 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.

ProductStrengthFormManufacturerHealth Canada statusDIN
AWIQLI2100 UNIT / 3 MLSOLUTIONNOVO NORDISK CANADA INCMARKETEDDIN 02546221
AWIQLI700 UNITSOLUTIONNOVO NORDISK CANADA INCMARKETEDDIN 02546205

Who else supplies INSULIN ICODEC worldwide?

Nexara tracks national medicine registries and published price lists across multiple markets. INSULIN ICODEC appears in 441 registered pack listings across 11 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.

Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.

How can I get it?

Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.

Request a quote for AWIQLI

Ordering questions

Who can buy this from Nexara?

Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.

Is there a minimum order?

Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.

What is the lead time?

Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.

Can Nexara supply this for a clinical trial?

Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.

Request a quote for AWIQLI

Health Canada Drug Product Database (DPD), DIN 02546213. Last reviewed 2026-09-08. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.